

# Nizoral

ketconazole

The first  
oral anti-fungal  
effective against  
all pathogenic  
fungi

**dosage:**

vaginal candidosis:	all other superficial and systemic fungal infections:
2 tablets once daily (with food) for 5 days	1 tablet daily (with food) until complete sympto- matic and mycological cure is obtained

**PRESCRIBING INFORMATION**

**Presentation:** white, flat, half scored uncoated tablets marked "Janssen" on one side and k/200 on the reverse. Each tablet contains 200 mg ketoconazole. **Uses:** Nizoral is an orally active antimycotic for the treatment in adults, of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and G.I. tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children, systemic mycoses and severe local infections where previous topical treatment has failed. **Side-effects, precautions, contra-indications:** contra-indicated in pregnancy. For maximal absorption Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H2 blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole, these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped.

Not all indications are as yet  
approved in all countries.

Janssen Pharmaceutica  
B-2340 Beerse, Belgium



# HISTORY OF THE BRITISH MEDICAL ASSOCIATION

Volume II 1932-1981

by

ELSTON GREY-TURNER  
CBE, MC, TD, MD, MRCS, LRCP  
(Secretary, BMA, 1976-79)

and

F M SUTHERLAND  
MA, FLA  
(Librarian, BMA, 1961-81)

A companion volume to the history of the BMA's first hundred years published in 1932, *The History of the BMA Volume II* covers the next 50 years. The authors, Dr E Grey-Turner, former secretary of the BMA, and Mr F Sutherland, former librarian of the BMA, describe the change in the BMA's role overseas, the baffling new ethical problems, and the expansion of the BMA's publishing activities. Their book is packed with fascinating information. Why did the BMA threaten the *Sunday Pictorial* at the beginning of the second world war? What did the presidents of the royal colleges say in their famous letter to Aneurin Bevan? What was the biggest award ever made to doctors by a Review Body? All these questions, and many more, are answered in this book.

Price: Hardback — £12.25 (US\$30.60)      Paperback — £10.00 (US\$25.00)

Volumes I & II in slip case — £19.25 (US\$48.10)

**Reduced price for BMA members only**

Hardback — £11.00 (US\$27.50)      Paperback — £9.00 (US\$22.50)

Volumes I & II in slip case — £17.25 (US\$43.15)

Order your copy now from: The Publisher, British Medical Journal,  
BMA House, Tavistock Square, London WC1H 9JR



Actifed.  
Taken around  
the world.

**Presentation. Actifed is available as tablets and syrup.** Each tablet contains 2.5 mg triprolidine hydrochloride and 60 mg pseudoephedrine hydrochloride. Each 5 ml of syrup contains 1.25 mg triprolidine hydrochloride and 30 mg pseudoephedrine hydrochloride.

**Indications** Symptomatic relief of upper respiratory congestion in the common cold, hay fever, vasomotor and allergic rhinitis, acute sinusitis, otitis barotrauma.

**Dosage** Three times a day: Adults and children over 12 years: 1 tablet or 10 ml. 6-12 years: 7.5 ml. 1-6 years: 5 ml. 3-12 months: 2.5 ml. **Contra-indications** Actifed is contra-indicated in persons hypersensitive to

pseudoephedrine or triprolidine and in those under treatment with MAO inhibitors and within 2 weeks of stopping such treatment. **Precautions** Although at recommended dosage pseudoephedrine has virtually no pressor effects in normotensive subjects, Actifed should be used with caution in patients with cardiovascular disorders. As with other antihistamine containing preparations, drowsiness may occur. In some patients the action of antihistamines may be potentiated by alcohol. 25 tablets. PL3/5003. 150 ml. PL3/5004.

**Actifed**<sup>TM</sup>  
Pseudoephedrine Hydrochloride BP  
Triprolidine Hydrochloride BP

The decongestant  
chosen by NASA



Further information is available on request.  
Wellcome Medical Division, The Wellcome Foundation Ltd., Crewe, Cheshire



#### Prescribing Information

**Name of product.** Natrilix tablets (indapamide hemihydrate).

**Presentation.** Pink biconvex sugar-coated tablets each containing 2.5 mg indapamide hemihydrate.

**Uses.** For the treatment of hypertension. Natrilix may be used as sole therapy or combined with other anti-hypertensive agents.

#### Dosage and administration.

**Adults.** The dosage is one tablet, containing 2.5 mg indapamide hemihydrate, daily to be taken in the morning. The action of Natrilix is progressive and the reduction in blood pressure may continue and not reach a maximum until several months after the start of therapy. A

larger dose than 2.5 mg Natrilix daily is not recommended as there is no appreciable additional anti-hypertensive effect but a diuretic effect may become apparent. If a single daily tablet of Natrilix does not achieve sufficient reduction in blood pressure, another anti-hypertensive agent may be added; those which have been used in combination with Natrilix include  $\beta$ -blockers, methyl dopa, clonidine and other adrenergic blocking agents. The co-administration of Natrilix with diuretics which may cause hypokalaemia is not recommended. There is no evidence of rebound hypertension on withdrawal of Natrilix.

**Children.** There is no experience of the use of this drug in children.

**Contra-indications, warnings, etc.** There are no absolute contra-indications to the use of Natrilix but caution should be exercised when prescribing it in cases of severe renal or hepatic impairment. As with all new drugs, the administration of Natrilix should be avoided during pregnancy although no teratological effects have been seen in animals. At doses higher than that recommended, Natrilix has a diuretic effect, therefore it is not recommended to prescribe it with a diuretic agent which may cause hypokalaemia. Also, slight weight loss has been reported in some

patients taking Natrilix. Reported side effects have included nausea and headache, but they are generally uncommon and mild in nature. Serum urate levels may rise slightly but there is no evidence that glucose tolerance is adversely affected.

**Overdosage.** Symptoms of overdosage would be those associated with a diuretic effect: electrolyte disturbances, hypotension and muscular weakness. Treatment would be symptomatic, directed at correcting the electrolyte abnormalities and gastric lavage or emesis should be considered.

**Pharmaceutical precautions.** Nil.  
**Legal category.** Available on prescription only.

**Package quantities.** Cartons of 30 and 60 tablets (containing respectively 2 and 3 push-through blister strips of 15 and 20 tablets).

**Further information.** No interactions have been reported between Natrilix and oral hypoglycaemic agents, anti-coagulants, uricosurics, and anti-inflammatory agents.

**Product licence number.** 0093/0022.

**Price.** Daily cost of treatment: 19.9 p.

**Reference:** 1. A multicentre open trial of indapamide in general practice. Murphy, M.A., Bowker, C.H., Postgraduate Medical Journal, 1981, 57 (Suppl. 2), 57-60.


Further information is available on request from



Servier Laboratories Limited,  
Fulmer Hall, Windmill Road, Fulmer,  
Slough SL3 6HH. Tel: Fulmer 2744.

## The logical choice

Select the correct figure from the six numbered ones



# Voltarol<sup>®</sup> diclofenac sodium for osteoarthritis

**Presentation** Tablets of 25 and 50mg diclofenac sodium; suppositories of 100mg diclofenac sodium. **Indications** Rheumatoid arthritis, osteoarthritis, low back pain, ankylosing spondylitis. **Dosage** Tablets: 75-150mg daily in two or three divided doses. Suppositories: one daily, usually administered at night. In more severe cases, combined therapy with tablets is recommended (daily dose should not exceed 150mg). **Contra-indications** Peptic ulceration; patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIs. **Precautions** Do not prescribe during pregnancy unless there are compelling reasons. Patients with a history of peptic ulcer, haematemesis or melaena, or with severe hepatic or renal insufficiency, should be kept under close surveillance. Voltarol has been reported to depress salicylate levels and vice versa; the clinical relevance of this is not yet clear. Use suppositories only with caution in patients with painful or irritable ano-rectal conditions. **Side-effects** Transient epigastric pain, nausea and diarrhoea, headache and slight dizziness have been reported, as occasionally have skin rash, peripheral oedema and abnormalities of serum transaminases and (very rarely) peptic ulcer and haematemesis or melaena. Local reactions to suppositories include itching, burning and increased frequency of bowel movement. **NHS price** Tablets 25mg: pack of 100 - £9.00; 50mg: pack of 100 - £17.50; Suppositories: pack of 10 - £2.98. **Product licence numbers** Tablets 25mg PL0001/0036, 50mg PL0001/0082, Suppositories 100mg PL0001/0083. Full prescribing information is available from **Geigy** Pharmaceuticals, Horsham, West Sussex.